JPWO2022165362A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022165362A5
JPWO2022165362A5 JP2023546482A JP2023546482A JPWO2022165362A5 JP WO2022165362 A5 JPWO2022165362 A5 JP WO2022165362A5 JP 2023546482 A JP2023546482 A JP 2023546482A JP 2023546482 A JP2023546482 A JP 2023546482A JP WO2022165362 A5 JPWO2022165362 A5 JP WO2022165362A5
Authority
JP
Japan
Prior art keywords
nucleic acid
composition
promoter
sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023546482A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024505570A5 (https=
JP2024505570A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/014601 external-priority patent/WO2022165362A2/en
Publication of JP2024505570A publication Critical patent/JP2024505570A/ja
Publication of JP2024505570A5 publication Critical patent/JP2024505570A5/ja
Publication of JPWO2022165362A5 publication Critical patent/JPWO2022165362A5/ja
Pending legal-status Critical Current

Links

JP2023546482A 2021-02-01 2022-01-31 神経学的疾患及び疼痛を治療するためのエピジェネティック遺伝子調節 Pending JP2024505570A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163144408P 2021-02-01 2021-02-01
US63/144,408 2021-02-01
PCT/US2022/014601 WO2022165362A2 (en) 2021-02-01 2022-01-31 Epigenetic gene regulation to treat neurological diseases and pain

Publications (3)

Publication Number Publication Date
JP2024505570A JP2024505570A (ja) 2024-02-06
JP2024505570A5 JP2024505570A5 (https=) 2025-02-10
JPWO2022165362A5 true JPWO2022165362A5 (https=) 2025-02-10

Family

ID=82653891

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023546482A Pending JP2024505570A (ja) 2021-02-01 2022-01-31 神経学的疾患及び疼痛を治療するためのエピジェネティック遺伝子調節

Country Status (7)

Country Link
US (1) US20240366795A1 (https=)
EP (1) EP4284927A4 (https=)
JP (1) JP2024505570A (https=)
CN (1) CN117203334A (https=)
AU (1) AU2022212277A1 (https=)
CA (1) CA3206936A1 (https=)
WO (1) WO2022165362A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024258906A1 (en) * 2023-04-17 2025-11-06 Sangamo Therapeutics, Inc. Zinc finger protein transcription factors for repressing nav1.7 expression
US20250057981A1 (en) * 2023-06-26 2025-02-20 Navega Therapeutics, Inc. Compositions and methods for reducing pain and inflammation through epigenetic modulation
WO2025076459A1 (en) * 2023-10-05 2025-04-10 Navega Therapeutics, Inc. Compositions and methods for epigenetic modulation of nav1.7
CN119139498B (zh) * 2024-09-26 2025-11-25 武汉泓宸创新生物科技有限公司 用于治疗与运动神经元损伤相关的疾病的药物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9624280B2 (en) * 2013-10-03 2017-04-18 Janssen Biotech, Inc. Protoxin-II variants and methods of use
WO2018035503A1 (en) * 2016-08-18 2018-02-22 The Regents Of The University Of California Crispr-cas genome engineering via a modular aav delivery system
CA3106446A1 (en) * 2017-07-13 2019-01-17 University Of Miami Method for managing pain
US20220202957A1 (en) * 2019-04-09 2022-06-30 The Regents Of The University Of California Long-lasting analgesia via targeted in vivo epigenetic repression

Similar Documents

Publication Publication Date Title
JP2021512649A5 (https=)
Mietzsch et al. OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1–12 vectors for gene therapy
Müller et al. Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors
Xu et al. Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes
Duan et al. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation
Koo et al. Triple trans-splicing adeno-associated virus vectors capable of transferring the coding sequence for full-length dystrophin protein into dystrophic mice
Recchia et al. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector
JP2024099770A5 (https=)
JPWO2021077000A5 (https=)
Driskell et al. Current status of gene therapy for inherited lung diseases
JP2020520643A5 (https=)
IL283278B1 (en) Liver-unique promoters and their uses
JP2020522269A5 (https=)
JP2021505133A5 (https=)
JPWO2022020616A5 (https=)
JP2021522836A5 (https=)
JPWO2019153009A5 (https=)
JP2024505570A (ja) 神経学的疾患及び疼痛を治療するためのエピジェネティック遺伝子調節
JPWO2022165362A5 (https=)
Sipo et al. Differential internalization and nuclear uncoating of self-complementary adeno-associated virus pseudotype vectors as determinants of cardiac cell transduction
GB2643476A (en) Compositions and methods for making epigenetic modifications
CN121925426A (zh) 肝脏去靶向衣壳
JPWO2021188729A5 (https=)
JPWO2020210542A5 (https=)
Cao et al. HPV-16 E1, E2 and E6 each complement the Ad5 helper gene set, increasing rAAV2 and wt AAV2 production